{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:59:45Z","timestamp":1785236385520,"version":"3.55.0"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Myopia is one of the most common eye diseases worldwide, with an increasing\nincidence observed in recent years. Globally, effective treatments for myopia have been\nextensively explored. In recent years, research on drugs for the treatment of myopia has become a\npopular topic in ophthalmology, with some breakthroughs having been achieved. Compared with\nsurgical treatment, drug treatment is easier for people to accept. Although the efficacy of some\ndrugs in delaying the development of myopia has been confirmed, the mechanism and site of action\nof some drugs are still not completely clear.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this study, we review the recent related research on drug therapy for myopia at home\nand abroad, describe the mechanism of various drugs in treating myopia, evaluate their clinical application\nvalue, and identify existing problems.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>These drugs include atropine, a series of anticholinergic drugs, dopamine agonists, 7-\nmethylxanthine, and intraocular pressure-lowering drugs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Results highlight the efficacy of atropine in myopia treatment with minimal side effects.\nAnticholinergic medications, such as atropine, have demonstrated efficacy in managing the\nprogression of myopia with a reduced incidence of adverse effects. The emphasis is placed on\nachieving better long-term effectiveness and minimizing the rebound effect after treatment is\nstopped. Furthermore, participating in outdoor activities and reducing eye strain are proven strategies\nfor preventing myopia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113894501359801250102055530","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T06:15:24Z","timestamp":1737526524000},"page":"382-393","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["New Advances in Drug Research for Myopia Control in Adolescents"],"prefix":"10.2174","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5231-7360","authenticated-orcid":true,"given":"Yu","family":"Liu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology,\nLuoyang, 471003, China"},{"name":"Henan International Joint Laboratory of Outflow Engineering, Sanmenxia Central\nHospital, and College of Clinical Medicine of Henan University of Science and Technology, Sanmenxia, 47200, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-6375","authenticated-orcid":true,"given":"Yalong","family":"Dang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China"},{"name":"Henan International Joint Laboratory of Outflow Engineering, Sanmenxia Central\nHospital, and College of Clinical Medicine of Henan University of Science and Technology, Sanmenxia, 47200, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"Holden B.A.","year":"2016","unstructured":"Holden B.A.; Fricke T.R.; Wilson D.A.; Jong M.; Naidoo K.S.; Sankaridurg P.; Wong T.Y.; Naduvilath T.J.; Resnikoff S.; Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology  2016,123(5),1036-1042","journal-title":"Ophthalmology"},{"key":"ref=2","first-page":"1277","volume":"15","author":"Barathi V.A.","year":"2009","unstructured":"Barathi V.A.; Weon S.R.; Beuerman R.W.; Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis  2009,15,1277-1293","journal-title":"Mol Vis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/02713680600770609","volume":"31","author":"Qu J.","year":"2006","unstructured":"Qu J.; Zhou X.; Xie R.; Zhang L.; Hu D.; Li H.; Lu F.; The presence of m1 to m5 receptors in human sclera: Evidence of the sclera as a potential site of action for muscarinic receptor antagonists. Curr Eye Res  2006,31(7-8),587-597","journal-title":"Curr Eye Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1167\/iovs.12-9943","volume":"53","author":"Arumugam B.","year":"2012","unstructured":"Arumugam B.; McBrien N.A.; Muscarinic antagonist control of myopia: Evidence for M4 and M1 receptor-based pathways in the inhibition of experimentally-induced axial myopia in the tree shrew. Invest Ophthalmol Vis Sci  2012,53(9),5827-5837","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0026-895X(25)09526-4","volume":"38","author":"Tucek S.","year":"1990","unstructured":"Tucek S.; Mus\u00edlkov\u00e1 J.; Nedoma J.; Proska J.; Shelkovnikov S.; Vorl\u00edcek J.; Positive cooperativity in the binding of alcuronium and N-methylscopolamine to muscarinic acetylcholine receptors. Mol Pharmacol  1990,38(5),674-680","journal-title":"Mol Pharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1167\/iovs.11-9031","volume":"53","author":"Lin H.J.","year":"2012","unstructured":"Lin H.J.; Wan L.; Chen W.C.; Lin J.M.; Lin C.J.; Tsai F.J.; Muscarinic acetylcholine receptor 3 is dominant in myopia progression. Invest Ophthalmol Vis Sci  2012,53(10),6519-6525","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.preteyeres.2017.06.003","volume":"61","author":"Zhou X.","year":"2017","unstructured":"Zhou X.; Pardue M.T.; Iuvone P.M.; Qu J.; Dopamine signaling and myopia development: What are the key challenges. Prog Retin Eye Res  2017,61,60-71","journal-title":"Prog Retin Eye Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1046\/j.1471-4159.2001.00145.x","volume":"76","author":"Megaw P.","year":"2001","unstructured":"Megaw P.; Morgan I.; Boelen M.; Vitreal dihydroxyphenylacetic acid (DOPAC) as an index of retinal dopamine release. J Neurochem  2001,76(6),1636-1644","journal-title":"J Neurochem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1023\/B:DOOP.0000019487.88486.0a","volume":"108","author":"Witkovsky P.","year":"2004","unstructured":"Witkovsky P.; Dopamine and retinal function. Doc Ophthalmol  2004,108(1),17-39","journal-title":"Doc Ophthalmol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.exer.2006.09.018","volume":"84","author":"McCarthy C.S.","year":"2007","unstructured":"McCarthy C.S.; Megaw P.; Devadas M.; Morgan I.G.; Dopaminergic agents affect the ability of brief periods of normal vision to prevent form-deprivation myopia. Exp Eye Res  2007,84(1),100-107","journal-title":"Exp Eye Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.exer.2010.08.021","volume":"91","author":"Nickla D.L.","year":"2010","unstructured":"Nickla D.L.; Totonelly K.; Dhillon B.; Dopaminergic agonists that result in ocular growth inhibition also elicit transient increases in choroidal thickness in chicks. Exp Eye Res  2010,91(5),715-720","journal-title":"Exp Eye Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"E003","DOI":"10.1017\/S0952523816000195","volume":"34","author":"Ward A.H.","year":"2017","unstructured":"Ward A.H.; Siegwart J.T.; Frost M.R.; Norton T.T.; Intravitreally-administered dopamine D2-like (and D4), but not D1-like, receptor agonists reduce form-deprivation myopia in tree shrews. Vis Neurosci  2017,34,E003","journal-title":"Vis Neurosci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1167\/iovs.61.6.47","volume":"61","author":"Huang F.","year":"2020","unstructured":"Huang F.; Wang Q.; Yan T.; Tang J.; Hou X.; Shu Z.; Wan F.; Yang Y.; Qu J.; Zhou X.; The role of the dopamine D2 receptor in form-deprivation myopia in mice: Studies with full and partial D2 receptor agonists and knockouts. Invest Ophthalmol Vis Sci  2020,61(6),47","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1167\/iovs.17-21574","volume":"59","author":"Zhang S.","year":"2018","unstructured":"Zhang S.; Yang J.; Reinach P.S.; Wang F.; Zhang L.; Fan M.; Ying H.; Pan M.; Qu J.; Zhou X.; Dopamine receptor subtypes mediate opposing effects on form deprivation myopia in pigmented guinea pigs. Invest Ophthalmol Vis Sci  2018,59(11),4441-4448","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1136\/bjo.83.12.1370","volume":"83","author":"Trier K.","year":"1999","unstructured":"Trier K.; Olsen E.B.; Kobayashi T.; Ribel-Madsen S.M.; Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine. Br J Ophthalmol  1999,83(12),1370-1375","journal-title":"Br J Ophthalmol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/j.1755-3768.2009.01559.x","volume":"88","author":"Cui D.","year":"2010","unstructured":"Cui D.; Trier K.; Zeng J.; Wu K.; Yu M.; Ge J.; Adenosine receptor protein changes in guinea pigs with form deprivation myopia. Acta Ophthalmol  2010,88(7),759-765","journal-title":"Acta Ophthalmol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0898-6568(03)00058-5","volume":"15","author":"Schulte G.","year":"2003","unstructured":"Schulte G.; Fredholm B.B.; Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal  2003,15(9),813-827","journal-title":"Cell Signal"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0031-6997(24)01396-6","volume":"51","author":"Fredholm B.B.","year":"1999","unstructured":"Fredholm B.B.; B\u00e4ttig K.; Holm\u00e9n J.; Nehlig A.; Zvartau E.E.; Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev  1999,51(1),83-133","journal-title":"Pharmacol Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0197-0186(00)00034-6","volume":"38","author":"Cunha R.A.","year":"2001","unstructured":"Cunha R.A.; Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: Different roles, different sources and different receptors. Neurochem Int  2001,38(2),107-125","journal-title":"Neurochem Int"},{"key":"ref=20","first-page":"133","volume":"5","author":"Nie H.H.","year":"2012","unstructured":"Nie H.H.; Huo L.J.; Yang X.; Gao Z.Y.; Zeng J.W.; Trier K.; Cui D.M.; Effects of 7-methylxanthine on form-deprivation myopia in pigmented rabbits. Int J Ophthalmol  2012,5(2),133-137","journal-title":"Int J Ophthalmol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/01658107.2018.1518988","volume":"43","author":"Kaur S.","year":"2019","unstructured":"Kaur S.; Sukhija J.; Khanna R.; Takkar A.; Singh M.; Diplopia after excessive smart phone usage. Neuroophthalmology  2019,43(5),323-326","journal-title":"Neuroophthalmology"},{"key":"ref=22","first-page":"2140","volume":"39","author":"Drexler W.","year":"1998","unstructured":"Drexler W.; Findl O.; Schmetterer L.; Hitzenberger C.K.; Fercher A.F.; Eye elongation during accommodation in humans: Differences between emmetropes and myopes. Invest Ophthalmol Vis Sci  1998,39(11),2140-2147","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.exer.2012.12.013","volume":"114","author":"Nickla D.L.","year":"2013","unstructured":"Nickla D.L.; Ocular diurnal rhythms and eye growth regulation: Where we are 50 years after Lauber. Exp Eye Res  2013,114,25-34","journal-title":"Exp Eye Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1167\/iovs.17-22890","volume":"59","author":"El-Nimri N.W.","year":"2018","unstructured":"El-Nimri N.W.; Wildsoet C.F.; Effects of topical latanoprost on intraocular pressure and myopia progression in young guinea pigs. Invest Ophthalmol Vis Sci  2018,59(6),2644-2651","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/opo.12052","volume":"33","author":"McBrien N.A.","year":"2013","unstructured":"McBrien N.A.; Stell W.K.; Carr B.; How does atropine exert its anti-myopia effects? Ophthalmic Physiol Opt  2013,33(3),373-378","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s10792-021-01875-1","volume":"41","author":"Hu S.","year":"2021","unstructured":"Hu S.; Ouyang S.; Liu H.; Zhang D.; Deng Z.; The effect of Wnt\/\u03b2- catenin pathway on the scleral remolding in the mouse during form deprivation. Int Ophthalmol  2021,41(9),3099-3107","journal-title":"Int Ophthalmol"},{"key":"ref=27","first-page":"76","volume":"29","author":"Li X.Q.","year":"2023","unstructured":"Li X.Q.; Kang P.; Zhou Y.; Ameliorative effect and mechanism of action of atropine on rats in a morphologic deprivation model of myopia. Hebei Med  2023,29(01),76-81","journal-title":"Hebei Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.7150\/ijms.38571","volume":"16","author":"Hsiao Y.T.","year":"2019","unstructured":"Hsiao Y.T.; Chang W.A.; Kuo M.T.; Lo J.; Lin H.C.; Yen M.C.; Jian S.F.; Chen Y.J.; Kuo P.L.; Systematic analysis of transcriptomic profile of the effects of low dose atropine treatment on scleral fibroblasts using next-generation sequencing and bioinformatics. Int J Med Sci  2019,16(12),1652-1667","journal-title":"Int J Med Sci"},{"key":"ref=29","first-page":"887","volume":"43","author":"Zheng Z.T.","year":"2023","unstructured":"Zheng Z.T.; Zhang L.Y.; Feng Y.; Effect of low concentration of atropine eye drops on retinal and choroidal thickness and microcirculation in myopic children and adolescents. Recent Adv Ophthalmol  2023,43(11),887-892","journal-title":"Recent Adv Ophthalmol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"Chua W.H.","year":"2006","unstructured":"Chua W.H.; Balakrishnan V.; Chan Y.H.; Tong L.; Ling Y.; Quah B.L.; Tan D.; Atropine for the treatment of childhood myopia. Ophthalmology  2006,113(12),2285-2291","journal-title":"Ophthalmology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10384-006-0380-7","volume":"51","author":"Fan D.S.P.","year":"2007","unstructured":"Fan D.S.P.; Lam D.S.C.; Chan C.K.M.; Fan A.H.; Cheung E.Y.Y.; Rao S.K.; Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: A pilot study. Jpn J Ophthalmol  2007,51(1),27-33","journal-title":"Jpn J Ophthalmol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.7150\/ijms.39365","volume":"17","author":"Zhu Q.","year":"2020","unstructured":"Zhu Q.; Tang Y.; Guo L.; Tighe S.; Zhou Y.; Zhang X.; Zhang J.; Zhu Y.; Hu M.; Efficacy and safety of 1% atropine on retardation of moderate myopia progression in chinese school children. Int J Med Sci  2020,17(2),176-181","journal-title":"Int J Med Sci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","volume":"34","author":"Polling J.R.","year":"2020","unstructured":"Polling J.R.; Tan E.; Driessen S.; Loudon S.E.; Wong H.L.; van der Schans A.; Tideman J.W.L.; Klaver C.C.W.; A 3-year follow-up study of atropine treatment for progressive myopia in Europeans. Eye (Lond)  2020,34(11),2020-2028","journal-title":"Eye (Lond)"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"Chia A.","year":"2012","unstructured":"Chia A.; Chua W.H.; Cheung Y.B.; Wong W.L.; Lingham A.; Fong A.; Tan D.; Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology  2012,119(2),347-354","journal-title":"Ophthalmology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"Chia A.","year":"2014","unstructured":"Chia A.; Chua W.H.; Wen L.; Fong A.; Goon Y.Y.; Tan D.; Atropine for the treatment of childhood myopia: Changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol  2014,157(2),451-457.e1","journal-title":"Am J Ophthalmol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ophtha.2015.10.012","volume":"123","author":"Morgan I.G.","year":"2016","unstructured":"Morgan I.G.; He M.; An important step forward in myopia prevention: Low-dose atropine. Ophthalmology  2016,123(2),232-233","journal-title":"Ophthalmology"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","volume":"135","author":"Gong Q.","year":"2017","unstructured":"Gong Q.; Janowski M.; Luo M.; Wei H.; Chen B.; Yang G.; Liu L.; Efficacy and adverse effects of atropine in childhood myopia: A meta-analysis. JAMA Ophthalmol  2017,135(6),624-630","journal-title":"JAMA Ophthalmol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/ICU.0000000000000367","volume":"28","author":"Leo S.W.","year":"2017","unstructured":"Leo S.W.; Current approaches to myopia control. Curr Opin Ophthalmol  2017,28(3),267-275","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"Chia A.","year":"2016","unstructured":"Chia A.; Lu Q.S.; Tan D.; Five-year clinical trial on atropine for the treatment of myopia 2: Myopia control with atropine 0.01% eyedrops. Ophthalmology  2016,123(2),391-399","journal-title":"Ophthalmology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/ICL.0000000000000499","volume":"44","author":"Cooper J.","year":"2018","unstructured":"Cooper J.; Tkatchenko A.V.; A review of current concepts of the etiology and treatment of myopia. Eye Contact Lens  2018,44(4),231-247","journal-title":"Eye Contact Lens"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/pharmaceutics14050900","volume":"14","author":"Chierigo A.","year":"2022","unstructured":"Chierigo A.; Desideri LF.; Traverso C.E.; Vagge A.; The role of atropine in preventing myopia progression: An update. Pharmaceutics  2022,14(5),900","journal-title":"Pharmaceutics"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ophtha.2020.06.004","volume":"127","author":"Li F.F.","year":"2020","unstructured":"Li F.F.; Kam K.W.; Zhang Y.; Tang S.M.; Young A.L.; Chen L.J.; Tham C.C.; Pang C.P.; Yam J.C.; Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: Low-concentration atropine for myopia progression study. Ophthalmology  2020,127(12),1603-1611","journal-title":"Ophthalmology"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12886-022-02385-z","volume":"22","author":"Wang M","year":"2022","unstructured":"Wang M; Cui C; Sui Y; Yu S A; Ma J X; Fu A C;  Effect of 0.02% and 0.01% atropine on astigmatism: A two-year clinical trial. BMC Ophthalmol  2022,22(1),161","journal-title":"BMC Ophthalmol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1136\/bjo.2008.147421","volume":"93","author":"Chia A.","year":"2009","unstructured":"Chia A.; Chua W-H.; Tan D.; Effect of topical atropine on astigmatism. Br J Ophthalmol  2009,93(6),799-802","journal-title":"Br J Ophthalmol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1046\/j.1475-1313.1995.9500074n.x","volume":"15","author":"Leech E.M.","year":"1995","unstructured":"Leech E.M.; Cottriall C.L.; McBrien N.A.; Pirenzepine prevents form deprivation myopia in a dose dependent manner. Ophthalmic Physiol Opt  1995,15(5),351-356","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref=46","first-page":"787","volume":"10","author":"Yin G.C.","year":"2004","unstructured":"Yin G.C.; Gentle A.; McBrien N.A.; Muscarinic antagonist control of myopia: A molecular search for the M1 receptor in chick. Mol Vis  2004,10,787-793","journal-title":"Mol Vis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1097\/00001756-200108080-00033","volume":"12","author":"Cottriall C.L.","year":"2001","unstructured":"Cottriall C.L.; Truong H.T.; McBrien N.A.; Inhibition of myopia development in chicks using himbacine: A role for M4 receptors? Neuroreport  2001,12(11),2453-2456","journal-title":"Neuroreport"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1089\/108076803321908392","volume":"19","author":"Bartlett J.D.","year":"2003","unstructured":"Bartlett J.D.; Niemann K.; Houde B.; Allred T.; Edmondson M.J.; Crockett R.S.; A tolerability study of pirenzepine ophthalmic gel in myopic children. J Ocul Pharmacol Ther  2003,19(3),271-279","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ophtha.2004.06.038","volume":"112","author":"Tan D.","year":"2005","unstructured":"Tan D.; Lam D.; Chua W.; Shuping D.; Crockett R.; One-year multicenter, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. Ophthalmology  2005,112(1),84-91","journal-title":"Ophthalmology"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1001\/archopht.122.11.1667","volume":"122","author":"Siatkowski R.M.","year":"2004","unstructured":"Siatkowski R.M.; Cotter S.; Miller J.M.; Scher C.A.; Crockett R.S.; Novack G.D.; Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: A 1-year, multicenter, double-masked, placebo-controlled parallel study. Arch Ophthalmol  2004,122(11),1667-1674","journal-title":"Arch Ophthalmol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jaapos.2007.10.014","volume":"12","author":"Siatkowski R.M.","year":"2008","unstructured":"Siatkowski R.M.; Cotter S.A.; Crockett R.S.; Miller J.M.; Novack G.D.; Zadnik K.; Two-year multicenter, randomized, double-masked, placebo-controlled, parallel safety and efficacy study of 2% pirenzepine ophthalmic gel in children with myopia. J AAPOS  2008,12(4),332-339","journal-title":"J AAPOS"},{"key":"ref=52","first-page":"42","volume":"42","author":"Dai S.Z.","year":"2006","unstructured":"Dai S.Z.; Zeng J.W.; Wang L.Y.; Effect of pirenzepine on form deprivation myopia in chicks and its possible mechanism. Zhonghua Yan Ke Za Zhi  2006,42(1),42-47","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s12013-014-0359-9","volume":"71","author":"Qian L.","year":"2015","unstructured":"Qian L.; Zhao H.; Li X.; Yin J.; Tang W.; Chen P.; Wang Q.; Zhang J.; Pirenzepine inhibits myopia in guinea pig model by regulating the balance of MMP-2 and TIMP-2 expression and increased tyrosine hydroxylase Levels. Cell Biochem Biophys  2015,71(3),1373-1378","journal-title":"Cell Biochem Biophys"},{"key":"ref=54","first-page":"1859","volume":"99","author":"Han W.T.","year":"2019","unstructured":"Han W.T.; Rong A.; Xu W.; Combination with different anticholinergic eyedrops for the treatment of children myopia. Zhonghua Yi Xue Za Zhi  2019,99(24),1859-1863","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref=55","first-page":"47","volume":"26","author":"Zhao J.","year":"2017","unstructured":"Zhao J.; Liu Z.S.; Zeng L.; Efficacy of racemic scopolamine eye drops in controlling the progression of myopia degree in 112 cases. China Pharmaceut  2017,26(24),47-49","journal-title":"China Pharmaceut"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.1999.15.85","volume":"15","author":"Shih Y.F.","year":"1999","unstructured":"Shih Y.F.; Chen C.H.; Chou A.C.; Ho T.C.; Lin L.L.K.; Hung P.T.; Effects of different concentrations of atropine on controlling myopia in myopic children. J Ocul Pharmacol Ther  1999,15(1),85-90","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=57","first-page":"40","volume":"18","author":"Li J.J.","year":"2021","unstructured":"Li J.J.; Observations on the effect of tropicamide ophthalmic solution in the treatment of myopia in children. J North Pharm  2021,18(04),40-41","journal-title":"J North Pharm"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.visres.2004.08.001","volume":"45","author":"Hupp\u00e9-Gourgues F.","year":"2005","unstructured":"Hupp\u00e9-Gourgues F.; Coud\u00e9 G.; Lachapelle P.; Casanova C.; Effects of the intravitreal administration of dopaminergic ligands on the b-wave amplitude of the rabbit electroretinogram. Vision Res  2005,45(2),137-145","journal-title":"Vision Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00006324-200402000-00012","volume":"81","author":"Schmid K.L.","year":"2004","unstructured":"Schmid K.L.; Wildsoet C.F.; Inhibitory effects of apomorphine and atropine and their combination on myopia in chicks. Optom Vis Sci  2004,81(2),137-147","journal-title":"Optom Vis Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1167\/iovs.14-15499","volume":"56","author":"Karouta C.","year":"2015","unstructured":"Karouta C.; Ashby R.S.; Correlation between light levels and the development of deprivation myopia. Invest Ophthalmol Vis Sci  2015,56(1),299-309","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ophtha.2007.12.019","volume":"115","author":"Rose K.A.","year":"2008","unstructured":"Rose K.A.; Morgan I.G.; Ip J.; Kifley A.; Huynh S.; Smith W.; Mitchell P.; Outdoor activity reduces the prevalence of myopia in children. Ophthalmology  2008,115(8),1279-1285","journal-title":"Ophthalmology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1167\/iovs.09-4689","volume":"51","author":"Ashby R.S.","year":"2010","unstructured":"Ashby R.S.; Schaeffel F.; The effect of bright light on lens compensation in chicks. Invest Ophthalmol Vis Sci  2010,51(10),5247-5253","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/iovs.62.4.25","volume":"62","author":"Thomson K.","year":"2021","unstructured":"Thomson K.; Morgan I.; Kelly T.; Karouta C.; Ashby R.; Coadministration with carbidopa enhances the antimyopic effects of levodopa in chickens. Invest Ophthalmol Vis Sci  2021,62(4),25","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"108233","DOI":"10.1016\/j.exer.2020.108233","volume":"200","author":"Thomson K.","year":"2020","unstructured":"Thomson K.; Karouta C.; Ashby R.; Topical application of dopaminergic compounds can inhibit deprivation myopia in chicks. Exp Eye Res  2020,200,108233","journal-title":"Exp Eye Res"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/archophthalmol.2010.178","volume":"128","author":"Repka M.X.","year":"2010","unstructured":"Repka M.X.; Kraker R.T.; Beck R.W.; Atkinson C.S.; Bacal D.A.; Bremer D.L.; Davis P.L.; Gearinger M.D.; Glaser S.R.; Hoover D.L.; Laby D.M.; Morrison D.G.; Rogers D.L.; Sala N.A.; Suh D.W.; Wheeler M.B.; Pilot study of levodopa dose as treatment for residual amblyopia in children aged 8 years to younger than 18 years. Arch Ophthalmol  2010,128(9),1215-1217","journal-title":"Arch Ophthalmol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1755-3768.2009.01688.x","volume":"89","author":"Cui D.","year":"2011","unstructured":"Cui D.; Trier K.; Zeng J.; Wu K.; Yu M.; Hu J.; Chen X.; Ge J.; Effects of 7-methylxanthine on the sclera in form deprivation myopia in guinea pigs. Acta Ophthalmol  2011,89(4),328-334","journal-title":"Acta Ophthalmol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1167\/iovs.17-22337","volume":"59","author":"Hung L.F.","year":"2018","unstructured":"Hung L.F.; Arumugam B.; Ostrin L.; Patel N.; Trier K.; Jong M.; Iii E.L.S.; The adenosine receptor antagonist, 7-Methylxanthine, alters emmetropizing responses in infant macaques. Invest Ophthalmol Vis Sci  2018,59(1),472-486","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12177-008-9013-3","volume":"1","author":"Trier K.","year":"2008","unstructured":"Trier K.; Munk Ribel-Madsen S.; Cui D.; Br\u00f8gger Christensen S.; Systemic 7-methylxanthine in retarding axial eye growth and myopia progression: A 36-month pilot study. J Ocul Biol Dis Infor  2008,1(2-4),85-93","journal-title":"J Ocul Biol Dis Infor"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1080\/01480545.2020.1833904","volume":"45","author":"Singh H.","year":"2022","unstructured":"Singh H.; Singh H.; Sahajpal N.S.; Paul S.; Kaur I.; Jain S.K.; Sub-chronic and chronic toxicity evaluation of 7-methylxanthine: A new molecule for the treatment of myopia. Drug Chem Toxicol  2022,45(3),1383-1394","journal-title":"Drug Chem Toxicol"},{"key":"ref=70","first-page":"785","volume":"23","author":"Liu Y.","year":"2017","unstructured":"Liu Y.; Wang Y.; Lv H.; Jiang X.; Zhang M.; Li X.; \u03b1-adrenergic agonist brimonidine control of experimentally induced myopia in guinea pigs: A pilot study. Mol Vis  2017,23,785-798","journal-title":"Mol Vis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1006\/exer.2000.0834","volume":"70","author":"Schmid K.L.","year":"2000","unstructured":"Schmid K.L.; Abbott M.; Humphries M.; Pyne K.; Wildsoet C.F.; Timolol lowers intraocular pressure but does not inhibit the development of experimental myopia in chick. Exp Eye Res  2000,70(5),659-666","journal-title":"Exp Eye Res"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12886-020-01610-x","volume":"20","author":"Dong L.","year":"2020","unstructured":"Dong L.; Li Y.F.; Wu H.T.; Di Kou H.; Lan Y.J.; Wang Y.X.; Jonas J.B.; Wei W.B.; Lens-induced myopization and intraocular pressure in young guinea pigs. BMC Ophthalmol  2020,20(1),343","journal-title":"BMC Ophthalmol"},{"key":"ref=73","first-page":"297","volume":"115","author":"Maeda N.","year":"2011","unstructured":"Maeda N.; New diagnostic methods for imaging the anterior segment of the eye to enable treatment modalities selection. Nippon Ganka Gakkai Zasshi  2011,115(3),297-322","journal-title":"Nippon Ganka Gakkai Zasshi"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501359801250102055530","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238649\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113894501359801250102055530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T16:42:06Z","timestamp":1747932126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238649\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113894501359801250102055530","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}